Recruiting
Phase 2

Avonex & Topamax

Sponsor:

Multiple Sclerosis Institute

Code:

NCT00217295

Conditions

Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Avonex and Topamax

Study Details

Brief summary:

This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical assessment scores to evaluate disease progression.

Conditions

Multiple Sclerosis

Study ID

NCT00217295

Start date

Apr, 2004

Status verified date

Jun, 2005

Completion date

Dec, 2007

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Inclusion Criteria:

Relapsing-remitting multiple sclerosis

-

Exclusion Criteria:

Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy -

Study Design

Enrollment

30 participants

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

Avonex and Topamax

Primary outcome measure

  • Safety and tolerability [ Time Frame: undefined ]

Central Contacts and Locations

Central contacts

Jeffrey I Greenstein, MD

215-985-2245

Locations

Multiple Sclerosis Institute

Recruiting

Philadelphia, Pennsylvania, United States, 19146

Contacts

Jeffrey I Greenstein, MD

215-985-2245

Iris J Gold, MBA

215-985-2245

Principal Investigator:

Jeffrey I Greenstein, MD

More Information

Sponsor

Multiple Sclerosis Institute

Last update posted

Sep 22, 2005

Last verified

Jun, 2005

Keywords

  • Relapsing-remitting multiple sclerosis
  • Brain atrophy
  • Disease progression

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Multiple Sclerosis Institute on 2005-09-22.